Rinvoq
Chemical Name | upadacitinib |
Dosage Form | Extended-release tablet (oral; 15 mg) |
Drug Class | Kinase inhibitors |
System | Musculoskeletal |
Company | AbbVie Inc. |
Approval Year | 2019 |
Indication
- Rinvoq is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.